OverviewChartNewsTraderScreen

BVT Call 230 BIIB 21.03.2025/  DE000VD3N4S0  /

Frankfurt Zert./VONT
1/10/2025  2:03:07 PM Chg.0.000 Bid4:12:19 PM Ask3:52:12 PM Underlying Strike price Expiration date Option type
0.041EUR 0.00% 0.035
Bid Size: 88,000		 0.172
Ask Size: 8,800		 Biogen Inc 230.00 USD 3/21/2025 Call
TeleTrader 10/30/2024 US opens lower after earnings, jobs, GDP data
TeleTrader 10/30/2024 Biogen's Q3 revenue down 3% to $2.5 billion
Newsfile Corp 10/10/2024 SAGE INVESTOR ALERT: Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to L...
GlobeNewswire 9/1/2024 SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Invest...
GlobeNewswire 8/29/2024 SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investo...
GlobeNewswire 8/26/2024 Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encoura...
GlobeNewswire 8/26/2024 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 8/22/2024 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire 8/19/2024 Tiziana Life Sciences Appoints New Chief Executive Officer
GlobeNewswire 8/19/2024 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...
GlobeNewswire 8/15/2024 Soleno Therapeutics Announces Updates to its Board of Directors
GlobeNewswire 8/15/2024 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire 8/8/2024 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 8/1/2024 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
TeleTrader 8/1/2024 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 8/1/2024 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 7/31/2024 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire 7/30/2024 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 7/30/2024 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...
GlobeNewswire 7/30/2024 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 7/26/2024 CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law...
GlobeNewswire 7/26/2024 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 7/26/2024 BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockh...
GlobeNewswire 7/22/2024 Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Fir...
GlobeNewswire 7/22/2024 DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of...